Trial
NCT04370236
INB03 for the Treatment of Pulmonary Complications From COVID-19
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Inmune Bio, Inc.
Collaborators
—
Condition
COVID-19
Intervention
INB03
Why stopped
Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-19